Free Trial
ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

About Bionomics Stock (ASX:BNO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
386,458 shs
Average Volume
N/A
Market Capitalization
$13.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Receive BNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNO Stock News Headlines

Bionomics Stock Price History
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
Bionomics ADR (BNOX) Earnings Dates & Reports
See More Headlines

BNO Stock Analysis - Frequently Asked Questions

Bionomics Limited (ASX:BNO) issued its earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share for the quarter. Bionomics had a negative net margin of 14,558.34% and a negative trailing twelve-month return on equity of 116.12%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include McDermott International (MDR), Pacific Drilling (PACDQ), OreCorp (ORR), ORBCOMM (ORBC), Lithium Power International (LPI), Lithium Australia (LIT) and Coca-Cola (KO).

Company Calendar

Last Earnings
2/15/2019
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BNO
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.91 million
Net Margins
-14,558.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.02 million
Price / Cash Flow
2.69
Book Value
A$1.09 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Market Cap
$13.22 million
Optionable
Not Optionable
Beta
2.13
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (ASX:BNO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners